Xlife Sciences AG (XLS) - Total Liabilities
Based on the latest financial reports, Xlife Sciences AG (XLS) has total liabilities worth CHF144.76 Million CHF (≈ $183.01 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Xlife Sciences AG to evaluate the company's liquid asset resilience ratio.
Xlife Sciences AG - Total Liabilities Trend (2019–2025)
This chart illustrates how Xlife Sciences AG's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Xlife Sciences AG's balance sheet.
Xlife Sciences AG Competitors by Total Liabilities
The table below lists competitors of Xlife Sciences AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Intergroup Corporation
NASDAQ:INTG
|
USA | $217.45 Million |
|
Suprema HQ Inc
KQ:094840
|
Korea | ₩7.40 Billion |
|
Richmond International Travel & Tours Co Ltd
TWO:2743
|
Taiwan | NT$1.96 Billion |
|
Genohco Inc.
KQ:361390
|
Korea | ₩42.57 Billion |
|
JHM Consolidation Bhd
KLSE:0127
|
Malaysia | RM195.34 Million |
|
Unitech Electronics Co. Ltd.
TW:3652
|
Taiwan | NT$674.40 Million |
|
Quantum Graphite Ltd
AU:QGL
|
Australia | AU$10.23 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Xlife Sciences AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See XLS equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xlife Sciences AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xlife Sciences AG (2019–2025)
The table below shows the annual total liabilities of Xlife Sciences AG from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF144.76 Million ≈ $183.01 Million |
-38.43% |
| 2024-12-31 | CHF235.11 Million ≈ $297.25 Million |
-3.57% |
| 2023-12-31 | CHF243.82 Million ≈ $308.25 Million |
-4.38% |
| 2022-12-31 | CHF255.00 Million ≈ $322.38 Million |
-5.15% |
| 2021-12-31 | CHF268.83 Million ≈ $339.87 Million |
+384.27% |
| 2020-12-31 | CHF55.51 Million ≈ $70.18 Million |
-2.00% |
| 2019-12-31 | CHF56.64 Million ≈ $71.61 Million |
-- |
About Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinica… Read more